Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Open-label Study Comparing the Combination of the BRAF Inhibitor, Dabrafenib and the MEK Inhibitor, Trametinib to the BRAF Inhibitor Vemurafenib in Subjects With Unresectable (Stage IIIc) or Metastatic (Stage IV) BRAF V600E/K Mutation Positive Cutaneous Melanoma
Brief Summary: This was a two-arm, open-label, randomized, Phase III study comparing dabrafenib (GSK2118436) and trametinib (GSK1120212) combination therapy with vemurafenib.


Options:
A: Arm Label: Dabrafenib plus Trametinib; Type: EXPERIMENTAL; Interventions: Drug: Dabrafenib, Drug: Trametinib | Arm Label: Vemurafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vemurafenib | Intervention Type: DRUG; Name: Dabrafenib; Assigned to Arm(s): Dabrafenib plus Trametinib | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Trametinib; Assigned to Arm(s): Dabrafenib plus Trametinib
B: Arm Label: Vemurafenib; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): Vemurafenib | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine
C: Arm Label: Pembrolizumab 2 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Pembrolizumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Investigator-Choice Chemotherapy (ICC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Dacarbazine, Drug: Temozolomide | Arm Label: ICC→Pembrolizumab 2 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Carboplatin, Drug: Paclitaxel, Drug: Dacarbazine, Drug: Temozolomide | Arm Label: ICC→Pembrolizumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Carboplatin, Drug: Paclitaxel, Drug: Dacarbazine, Drug: Temozolomide | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): ICC→Pembrolizumab 10 mg/kg, ICC→Pembrolizumab 2 mg/kg, Pembrolizumab 10 mg/kg, Pembrolizumab 2 mg/kg | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): ICC→Pembrolizumab 10 mg/kg, ICC→Pembrolizumab 2 mg/kg, Investigator-Choice Chemotherapy (ICC) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): ICC→Pembrolizumab 10 mg/kg, ICC→Pembrolizumab 2 mg/kg, Investigator-Choice Chemotherapy (ICC) | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): ICC→Pembrolizumab 10 mg/kg, ICC→Pembrolizumab 2 mg/kg, Investigator-Choice Chemotherapy (ICC) | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): ICC→Pembrolizumab 10 mg/kg, ICC→Pembrolizumab 2 mg/kg, Investigator-Choice Chemotherapy (ICC)
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: AZD6244, Drug: Dacarbazine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Dacarbazine, Drug: Placebo | Intervention Type: DRUG; Name: AZD6244; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: A